| Description |
UCB-9260, an orally active compound, inhibits TNF signalling by stabilising an asymmetric form of the trimer. UCB-9260 is selective for TNF over other superfamily members, and binds TNF with a similar Kd of 13 nM[1].
|
| Related Catalog |
|
| In Vitro |
UCB-9260 (0-10 μM) inhibits NF-κB with a geometric mean IC50 of 202 nM after TNF (10 pM) stimulation in in Hek-293 cells[1]. UCB-9260 inhibits TNF-dependent cytotoxicity with a geometric mean IC50 of 116 nM and a geometric mean IC50 of 120 nM, using human and mouse TNF, respectively[1].
|
| In Vivo |
UCB-9260 (150 mg/kg; p.o.;twice daily for 7 days) shows a significant reduction of the clinical score[1]. UCB-9260 (10-300 mg/kg; p.o.) dose-dependently inhibits human and mouse TNF-induced neutrophil recruitment to the peritoneal compartment in adult male Balb/c mice[1]. Animal Model: Aged 6-8 weeks adult male Balb/c mice ( CAIA model)[1] Dosage: 150 mg/kg Administration: p.o.; twice daily for 7days Result: Showed a significant reduction of the clinical score.
|
| References |
[1]. O'Connell J, et al.Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer.Nat Commun. 2019 Dec 19;10(1):5795.
|
